New Enterprise Associates 14, L.p. - Net Worth and Insider Trading

New Enterprise Associates 14, L.p. Net Worth

The estimated net worth of New Enterprise Associates 14, L.p. is at least $209 Million dollars as of 2024-12-26. New Enterprise Associates 14, L.p. is the 10% Owner of Oyster Point Pharma Inc and owns about 5,925,287 shares of Oyster Point Pharma Inc (OYST) stock worth over $66 Million. New Enterprise Associates 14, L.p. is the 10% Owner of Adaptimmune Therapeutics PLC and owns about 82,978,668 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $48 Million. New Enterprise Associates 14, L.p. is also the 10% Owner of Casper Sleep Inc and owns about 6,222,412 shares of Casper Sleep Inc (CSPR) stock worth over $42 Million. Besides these, New Enterprise Associates 14, L.p. also holds Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Champions Oncology Inc (CSBR) , Surface Oncology Inc (SURF) , Galera Therapeutics Inc (GRTX) , TRACON Pharmaceuticals Inc (TCON) , Appian Corp (APPN) . Details can be seen in New Enterprise Associates 14, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that New Enterprise Associates 14, L.p. has not made any transactions after 2022-04-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of New Enterprise Associates 14, L.p.

New Enterprise Associates 14, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, New Enterprise Associates 14, L.p. owns 18 companies in total, including Mersana Therapeutics Inc (MRSN) , Surface Oncology Inc (SURF) , and Imara Inc (IMRA) among others .

Click here to see the complete history of New Enterprise Associates 14, L.p.’s form 4 insider trades.

Insider Ownership Summary of New Enterprise Associates 14, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
MRSN	Mersana Therapeutics Inc	2019-08-28	10 percent owner
SURF	Surface Oncology Inc	2020-05-20	10 percent owner
IMRA	Imara Inc	2022-04-06	10 percent owner
		2020-03-06	10 percent owner
		2020-02-10	10 percent owner
		2019-11-12	10 percent owner
		2019-11-04	10 percent owner
		2018-09-07	10 percent owner
		2018-05-01	10 percent owner
		2018-03-27	10 percent owner
		2017-11-27	10 percent owner
		2015-09-30	10 percent owner
		2018-01-01	10 percent owner
		2016-07-29	10 percent owner
		2015-10-14	10 percent owner
		2014-07-31	10 percent owner
		2022-08-03	10 percent owner
		2020-03-11	10 percent owner

New Enterprise Associates 14, L.p. Latest Holdings Summary

New Enterprise Associates 14, L.p. currently owns a total of 10 stocks. Among these stocks, New Enterprise Associates 14, L.p. owns 5,925,287 shares of Oyster Point Pharma Inc (OYST) as of November 4, 2019, with a value of $66 Million and a weighting of 31.67%. New Enterprise Associates 14, L.p. owns 82,978,668 shares of Adaptimmune Therapeutics PLC (ADAP) as of September 7, 2018, with a value of $48 Million and a weighting of 22.98%. New Enterprise Associates 14, L.p. also owns 6,222,412 shares of Casper Sleep Inc (CSPR) as of February 10, 2020, with a value of $42 Million and a weighting of 20.19%. The other 7 stocks Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Champions Oncology Inc (CSBR) , Surface Oncology Inc (SURF) , Galera Therapeutics Inc (GRTX) , TRACON Pharmaceuticals Inc (TCON) , Appian Corp (APPN) have a combined weighting of 25.16% among all his current holdings.

Latest Holdings of New Enterprise Associates 14, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
OYST	Oyster Point Pharma Inc	2019-11-04	5,925,287	11.17	66,185,456
ADAP	Adaptimmune Therapeutics PLC	2018-09-07	82,978,668	0.58	48,028,053
CSPR	Casper Sleep Inc	2020-02-10	6,222,412	6.78	42,187,953
MRSN	Mersana Therapeutics Inc	2019-08-28	11,959,520	1.62	19,374,422
IMRA	Imara Inc	2022-04-06	2,611,050	6.32	16,501,836
CSBR	Champions Oncology Inc	2020-03-06	1,713,720	7.87	13,486,976
SURF	Surface Oncology Inc	2020-05-20	2,892,877	1.07	3,095,378
GRTX	Galera Therapeutics Inc	2019-11-12	4,358,047	0.03	129,695
TCON	TRACON Pharmaceuticals Inc	2018-03-27	17,330	0.03	558
APPN	Appian Corp	2017-11-27	0	34.51	0

Holding Weightings of New Enterprise Associates 14, L.p.

New Enterprise Associates 14, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, New Enterprise Associates 14, L.p. has made a total of 0 transactions in Oyster Point Pharma Inc (OYST) over the past 5 years. The most-recent trade in Oyster Point Pharma Inc is the acquisition of 935,000 shares on November 4, 2019, which cost New Enterprise Associates 14, L.p. around $15 Million.

According to the SEC Form 4 filings, New Enterprise Associates 14, L.p. has made a total of 0 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years. The most-recent trade in Adaptimmune Therapeutics PLC is the acquisition of 3,000,000 shares on September 7, 2018, which cost New Enterprise Associates 14, L.p. around $5 Million.

According to the SEC Form 4 filings, New Enterprise Associates 14, L.p. has made a total of 1 transactions in Casper Sleep Inc (CSPR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Casper Sleep Inc is the acquisition of 1,250,000 shares on February 10, 2020, which cost New Enterprise Associates 14, L.p. around $15 Million.

More details on New Enterprise Associates 14, L.p.'s insider transactions can be found in the Insider Trading History of New Enterprise Associates 14, L.p. table.

Insider Trading History of New Enterprise Associates 14, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

New Enterprise Associates 14, L.p. Trading Performance

GuruFocus tracks the stock performance after each of New Enterprise Associates 14, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by New Enterprise Associates 14, L.p. is 16.2%. GuruFocus also compares New Enterprise Associates 14, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by New Enterprise Associates 14, L.p. within 3 months outperforms 7 times out of 13 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how New Enterprise Associates 14, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of New Enterprise Associates 14, L.p.

Average Return

Average return per transaction

Outperforming Transactions

4 out of 13 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	3.37
Relative Return to S&P 500(%)	1.31

New Enterprise Associates 14, L.p. Ownership Network

Ownership Network List of New Enterprise Associates 14, L.p.

No Data

Ownership Network Relation of New Enterprise Associates 14, L.p.

New Enterprise Associates 14, L.p. Owned Company Details

What does Mersana Therapeutics Inc do?

Who are the key executives at Mersana Therapeutics Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Mersana Therapeutics Inc. Other key executives at Mersana Therapeutics Inc include SVP & Chief Development Officer Mohan Bala , Sr. VP & Finance & Product stgy Brian Deschuytner , and VP & Controller Ashish Mandelia .

Mersana Therapeutics Inc (MRSN) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Mersana Therapeutics Inc (MRSN). Other recent insider transactions involving Mersana Therapeutics Inc (MRSN) include a net sale of 20,914 shares made by Mohan Bala , a net sale of 24,096 shares made by Timothy B Lowinger , and a net sale of 23,014 shares made by Brian Deschuytner .

In summary, during the past 3 months, insiders sold 64,848 shares of Mersana Therapeutics Inc (MRSN) in total and bought 0 shares, with a net sale of 64,848 shares. During the past 18 months, 184,420 shares of Mersana Therapeutics Inc (MRSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 184,420 shares.

Mersana Therapeutics Inc (MRSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mersana Therapeutics Inc Insider Transactions

No Available Data

What does Surface Oncology Inc do?

Who are the key executives at Surface Oncology Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Surface Oncology Inc. Other key executives at Surface Oncology Inc include Deputy GC Chandra Adams , Chief Medical Officer Alison Oneill , and See Remarks Jessica Fees .

Surface Oncology Inc (SURF) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Surface Oncology Inc (SURF). Other recent insider transactions involving Surface Oncology Inc (SURF) include a net sale of 16,713 shares made by Robert W. Ross , a net sale of 9,434 shares made by Jessica Fees , and a net sale of 7,042 shares made by Alison Oneill .

In summary, during the past 3 months, insiders sold 0 shares of Surface Oncology Inc (SURF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 37,090 shares of Surface Oncology Inc (SURF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 37,090 shares.

Surface Oncology Inc (SURF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Surface Oncology Inc Insider Transactions

No Available Data

What does Imara Inc do?

Who are the key executives at Imara Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Imara Inc. Other key executives at Imara Inc include director & President & CEO Rahul D. Ballal , See Remarks Michael Gray , and 10 percent owner Braden Michael Leonard .

Imara Inc (IMRA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Imara Inc (IMRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Imara Inc (IMRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Imara Inc (IMRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Imara Inc Insider Transactions

No Available Data

What does Champions Oncology Inc do?

Who are the key executives at Champions Oncology Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Champions Oncology Inc. Other key executives at Champions Oncology Inc include director & President Ronnie Morris , 10 percent owner Roger H Lee , and 10 percent owner Michael Maurice Brown .

Champions Oncology Inc (CSBR) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Champions Oncology Inc (CSBR). Other recent insider transactions involving Champions Oncology Inc (CSBR) include a net purchase of 75,504 shares made by Daniel Newman Mendelson ,

In summary, during the past 3 months, insiders sold 0 shares of Champions Oncology Inc (CSBR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Champions Oncology Inc (CSBR) were sold and 75,504 shares were bought by its insiders, resulting in a net purchase of 75,504 shares.

Champions Oncology Inc (CSBR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Champions Oncology Inc Insider Transactions

No Available Data

What does Casper Sleep Inc do?

Who are the key executives at Casper Sleep Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Casper Sleep Inc. Other key executives at Casper Sleep Inc include Chief Financial Officer Michael P. Monahan , director & Chief Strategy Officer Neil Parikh , and CCO & President Emilie Arel .

Casper Sleep Inc (CSPR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Casper Sleep Inc (CSPR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Casper Sleep Inc (CSPR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Casper Sleep Inc (CSPR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Casper Sleep Inc Insider Transactions

No Available Data

What does Galera Therapeutics Inc do?

Who are the key executives at Galera Therapeutics Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Galera Therapeutics Inc. Other key executives at Galera Therapeutics Inc include director & President and CEO Mel Sorensen , Chief Commercial Officer Mark Bachleda , and Chief Financial Officer Chris Degnan .

Galera Therapeutics Inc (GRTX) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Galera Therapeutics Inc (GRTX). Other recent insider transactions involving Galera Therapeutics Inc (GRTX) include a net purchase of 3,712,809 shares made by , and a net sale of 67,015 shares made by Mel Sorensen .

In summary, during the past 3 months, insiders sold 0 shares of Galera Therapeutics Inc (GRTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 67,015 shares of Galera Therapeutics Inc (GRTX) were sold and 3,712,809 shares were bought by its insiders, resulting in a net purchase of 3,645,794 shares.

Galera Therapeutics Inc (GRTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Galera Therapeutics Inc Insider Transactions

No Available Data

What does Oyster Point Pharma Inc do?

Who are the key executives at Oyster Point Pharma Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Oyster Point Pharma Inc. Other key executives at Oyster Point Pharma Inc include 10 percent owner Versant Venture Capital Vi, L.p. , director & 10 percent owner Link William J Phd , and Chief Commercial Officer John Snisarenko .

Oyster Point Pharma Inc (OYST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oyster Point Pharma Inc (OYST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oyster Point Pharma Inc (OYST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oyster Point Pharma Inc (OYST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oyster Point Pharma Inc Insider Transactions

No Available Data

What does Adaptimmune Therapeutics PLC do?

Who are the key executives at Adaptimmune Therapeutics PLC?

New Enterprise Associates 14, L.p. is the 10 percent owner of Adaptimmune Therapeutics PLC. Other key executives at Adaptimmune Therapeutics PLC include Chief Commercial Officer Cintia Piccina , Chief Medical Officer Elliot Norry , and Chief Operating Officer Bertrand William C Jr .

Adaptimmune Therapeutics PLC (ADAP) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Adaptimmune Therapeutics PLC (ADAP). Other recent insider transactions involving Adaptimmune Therapeutics PLC (ADAP) include a net sale of 73,322 shares made by Adrian Rawcliffe , a net sale of 35,120 shares made by John Lunger , and a net sale of 32,818 shares made by Bertrand William C Jr .

In summary, during the past 3 months, insiders sold 0 shares of Adaptimmune Therapeutics PLC (ADAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 245,864 shares of Adaptimmune Therapeutics PLC (ADAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 245,864 shares.

Adaptimmune Therapeutics PLC (ADAP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adaptimmune Therapeutics PLC Insider Transactions

No Available Data

What does MuleSoft Inc do?

Who are the key executives at MuleSoft Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of MuleSoft Inc. Other key executives at MuleSoft Inc include 10 percent owner Scott D Sandell , 10 percent owner Patrick J Kerins , and 10 percent owner Florence Anthony A. Jr. .

MuleSoft Inc (MULE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of MuleSoft Inc (MULE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of MuleSoft Inc (MULE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

MuleSoft Inc (MULE)'s detailed insider trading history can be found in Insider Trading Tracker table.

MuleSoft Inc Insider Transactions

No Available Data

What does TRACON Pharmaceuticals Inc do?

Who are the key executives at TRACON Pharmaceuticals Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of TRACON Pharmaceuticals Inc. Other key executives at TRACON Pharmaceuticals Inc include 10 percent owner Opaleye Management Inc. , director & President and CEO Charles Theuer , and Chief Operating Officer Bonne J. Adams .

TRACON Pharmaceuticals Inc (TCON) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in TRACON Pharmaceuticals Inc (TCON). Other recent insider transactions involving TRACON Pharmaceuticals Inc (TCON) include a net sale of 4,764,008 shares made by Opaleye Management Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of TRACON Pharmaceuticals Inc (TCON) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 238,200 shares of TRACON Pharmaceuticals Inc (TCON) were sold and 0 shares were bought by its insiders, resulting in a net sale of 238,200 shares.

TRACON Pharmaceuticals Inc (TCON)'s detailed insider trading history can be found in Insider Trading Tracker table.

TRACON Pharmaceuticals Inc Insider Transactions

No Available Data

What does Appian Corp do?

Who are the key executives at Appian Corp?

New Enterprise Associates 14, L.p. is the 10 percent owner of Appian Corp. Other key executives at Appian Corp include 10 percent owner Abdiel Qualified Master Fund Lp , director & 10 percent owner Biddle Albert G.w. Iii , and Chief Revenue Officer Christopher M Jones .

Appian Corp (APPN) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Appian Corp (APPN). Other recent insider transactions involving Appian Corp (APPN) include a net purchase of 57,584 shares made by Abdiel Qualified Master Fund Lp , a net sale of 30,000 shares made by Christopher Winters , and a net sale of 13,068 shares made by Mark Matheos .

In summary, during the past 3 months, insiders sold 700 shares of Appian Corp (APPN) in total and bought 10,265 shares, with a net purchase of 9,565 shares. During the past 18 months, 4,279,918 shares of Appian Corp (APPN) were sold and 4,300,234 shares were bought by its insiders, resulting in a net purchase of 20,316 shares.

Appian Corp (APPN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Appian Corp Insider Transactions

No Available Data

What does Synlogic Inc do?

Who are the key executives at Synlogic Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Synlogic Inc. Other key executives at Synlogic Inc include Chief Operating Officer Antoine Awad , Chief Financial Officer Michael Vangsted Jensen , and Chief Medical Officer Aoife Brennan .

Synlogic Inc (SYBX) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Synlogic Inc (SYBX). Other recent insider transactions involving Synlogic Inc (SYBX) include a net sale of 267 shares made by , and a net sale of 372 shares made by Antoine Awad .

In summary, during the past 3 months, insiders sold 79 shares of Synlogic Inc (SYBX) in total and bought 0 shares, with a net sale of 79 shares. During the past 18 months, 639 shares of Synlogic Inc (SYBX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 639 shares.

Synlogic Inc (SYBX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Synlogic Inc Insider Transactions

No Available Data

What does Strongbridge Biopharma PLC do?

Who are the key executives at Strongbridge Biopharma PLC?

New Enterprise Associates 14, L.p. is the 10 percent owner of Strongbridge Biopharma PLC. Other key executives at Strongbridge Biopharma PLC include 10 percent owner Cdk Associates, L.l.c. , 10 percent owner Caxton Corp , and 10 percent owner Bruce Kovner .

Strongbridge Biopharma PLC (SBBP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Strongbridge Biopharma PLC (SBBP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Strongbridge Biopharma PLC (SBBP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Strongbridge Biopharma PLC (SBBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Strongbridge Biopharma PLC Insider Transactions

No Available Data

What does Interleukin Genetics Inc do?

Who are the key executives at Interleukin Genetics Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Interleukin Genetics Inc. Other key executives at Interleukin Genetics Inc include 10 percent owner Patrick J Kerins , 10 percent owner Growth Equity Opportunities Fund III, LLC , and Interim CFO Stephen J. Dipalma .

Interleukin Genetics Inc (ILIU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Interleukin Genetics Inc (ILIU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Interleukin Genetics Inc (ILIU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Interleukin Genetics Inc (ILIU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Interleukin Genetics Inc Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include director & 10 percent owner Armistice Capital Master Fund Ltd. , 10 percent owner Caissa Capital Management Ltd. , and Interim CFO Christopher Ryan Sullivan .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Avalo Therapeutics Inc (AVTX). Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net sale of 3,683,542 shares made by Armistice Capital Master Fund Ltd. , and a net purchase of 1,000 shares made by June Sherie Almenoff .

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 1,000 shares, with a net purchase of 1,000 shares. During the past 18 months, 15,348 shares of Avalo Therapeutics Inc (AVTX) were sold and 1,000 shares were bought by its insiders, resulting in a net sale of 14,348 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does Loxo Oncology Inc do?

Who are the key executives at Loxo Oncology Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Loxo Oncology Inc. Other key executives at Loxo Oncology Inc include Senior VP of Finance Jennifer Burstein , director & President & CEO Joshua H. Bilenker , and director & 10 percent owner Steve Elms .

Loxo Oncology Inc (LOXO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Loxo Oncology Inc (LOXO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Loxo Oncology Inc (LOXO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Loxo Oncology Inc (LOXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Loxo Oncology Inc Insider Transactions

No Available Data

What does ZeroFox Holdings Inc do?

Who are the key executives at ZeroFox Holdings Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of ZeroFox Holdings Inc. Other key executives at ZeroFox Holdings Inc include director & See Remarks James Christopher Foster , Chief Marketing Officer Prestridge Iii John R , and Chief Technology Officer Michael Morgan Price .

ZeroFox Holdings Inc (ZFOX) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in ZeroFox Holdings Inc (ZFOX). Other recent insider transactions involving ZeroFox Holdings Inc (ZFOX) include a net sale of 224,517 shares made by James Christopher Foster , a net sale of 59,691 shares made by Timothy S Bender , and a net sale of 54,174 shares made by Michael Morgan Price .

In summary, during the past 3 months, insiders sold 0 shares of ZeroFox Holdings Inc (ZFOX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 515,540 shares of ZeroFox Holdings Inc (ZFOX) were sold and 51,000 shares were bought by its insiders, resulting in a net sale of 464,540 shares.

ZeroFox Holdings Inc (ZFOX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZeroFox Holdings Inc Insider Transactions

No Available Data

What does Enliven Therapeutics Inc do?

Who are the key executives at Enliven Therapeutics Inc?

New Enterprise Associates 14, L.p. is the 10 percent owner of Enliven Therapeutics Inc. Other key executives at Enliven Therapeutics Inc include Chief Financial Officer Benjamin Hohl , director & President and CEO Samuel Kintz , and Chief Operating Officer Anish Patel .

Enliven Therapeutics Inc (ELVN) Insider Trades Summary

Over the past 18 months, New Enterprise Associates 14, L.p. made no insider transaction in Enliven Therapeutics Inc (ELVN). Other recent insider transactions involving Enliven Therapeutics Inc (ELVN) include a net sale of 93,564 shares made by Benjamin Hohl , a net sale of 240,342 shares made by Samuel Kintz , and a net sale of 239,847 shares made by Joseph P Lyssikatos .

In summary, during the past 3 months, insiders sold 157,819 shares of Enliven Therapeutics Inc (ELVN) in total and bought 0 shares, with a net sale of 157,819 shares. During the past 18 months, 4,860,959 shares of Enliven Therapeutics Inc (ELVN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,860,959 shares.

Enliven Therapeutics Inc (ELVN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Enliven Therapeutics Inc Insider Transactions

No Available Data

New Enterprise Associates 14, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for New Enterprise Associates 14, L.p.. You might contact New Enterprise Associates 14, L.p. via mailing address: 1954 Greenspring Drive, Suite 600, Timonium Md 21093.

Discussions on New Enterprise Associates 14, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.